

Supplementary Online Content

Nomura H, Aoki D, Michimae H, et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression. *JAMA Oncol*. Published online March 21, 2019. doi:10.1001/jamaoncol.2019.0001

eTable 1. Baseline patient characteristics

eTable 2. Frequency of grade 3 or higher adverse events

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Baseline patient characteristics

Characteristics	AP (n=263)		DP (n=263)		TC (n=262)	
	No.	(%)	No.	(%)	No.	(%)
Age, years						
Median	58		59		59	
Range	22-74		29-74		31-74	
ECOG performance status						
0	233	(88.6)	233	(88.6)	217	(82.8)
1	28	(10.6)	27	(10.3)	39	(14.9)
2	0	(0.0)	1	(0.4)	3	(1.1)
Unknown	2	(0.8)	2	(0.8)	3	(1.1)
Surgical stage (FIGO 1988)*						
IC	54	(20.5)	59	(22.4)	58	(22.1)
II	26	(9.9)	21	(8.0)	24	(9.2)
III	167	(63.5)	169	(64.3)	158	(60.3)
IV	16	(6.1)	14	(5.3)	22	(8.4)
Histologic type						
Endometrioid carcinoma	218	(82.9)	213	(81.0)	202	(77.1)
Serous carcinoma	20	(7.6)	17	(6.5)	20	(7.6)
Clear cell carcinoma	7	(2.7)	9	(3.4)	9	(3.4)
Mucinous carcinoma	1	(0.4)	3	(1.1)	3	(1.1)
Mixed carcinoma	9	(3.4)	8	(3.0)	14	(5.3)
Others	8	(3.0)	13	(4.9)	14	(5.3)
Histologic grade*						
Grade 1	62	(23.6)	68	(25.9)	61	(23.3)
Grade 2	108	(41.1)	98	(37.3)	105	(40.1)
Grade 3	71	(27.0)	74	(28.1)	65	(24.8)
Unknown/Not applicable	22	(8.3)	23	(8.7)	31	(11.8)
Lymph node sampling/dissection						
Pelvic only	99	(37.6)	117	(44.5)	115	(43.9)
Pelvic and para-aortic	162	(61.6)	146	(55.5)	146	(55.7)
No data	2	(0.8)	0	(0.0)	1	(0.4)

Size of residual tumor						
No residual	253	(96.2)	253	(96.2)	251	(95.8)
< 1cm	5	(1.9)	4	(1.5)	5	(1.9)
≥ 1cm	5	(1.9)	6	(2.3)	6	(2.3)

ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; AP,

doxorubicin plus cisplatin; DP, docetaxel plus cisplatin; TC, paclitaxel plus carboplatin.

* Stratification factor.

eTable 2. Frequency of grade 3 or higher adverse events

Adverse event	AP (n=261)		DP (n=261)			TC (n=259)		
	No.	(%)	No.	(%)	p value*	No.	(%)	p value*
Leukocytes	218	(83.5)	194	(74.3)	0.01	171	(66.0)	<0.001
Neutrophils	252	(96.6)	233	(89.3)	<0.01	237	(91.5)	0.02
Platelets	33	(12.6)	2	(0.8)	<0.001	50	(19.3)	0.04
Hemoglobin	89	(34.1)	44	(16.9)	<0.001	75	(29.0)	0.21
Febrile neutropenia	41	(15.7)	16	(6.1)	<0.01	12	(4.6)	<0.001
Infection with grade 3 or 4 neutrophils	21	(8.0)	9	(3.4)	0.02	6	(2.3)	<0.01
ALT	4	(1.5)	3	(1.1)	0.70	6	(2.3)	0.52
Creatinine	0	(0.0)	2	(0.8)	0.16	0	(0.0)	--
Allergic reaction	0	(0.0)	4	(1.5)	0.04	2	(0.8)	0.16
Anorexia	19	(7.3)	18	(6.9)	0.86	5	(1.9)	<0.01
Diarrhea	2	(0.8)	6	(2.3)	0.15	0	(0.0)	0.16
Nausea	16	(6.1)	13	(5.0)	0.57	2	(0.8)	<0.01
Vomiting	15	(5.7)	12	(4.6)	0.55	2	(0.8)	<0.01
Pain-Muscle	0	(0.0)	0	(0.0)	--	8	(3.1)	<0.01
Neuropathy-motor	0	(0.0)	1	(0.4)	0.32	5	(1.9)	0.02
Neuropathy- sensory	0	(0.0)	5	(1.9)	0.03	11	(4.2)	<0.01

NOTE. Classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0).

ALT, alanine transaminase; AP, doxorubicin plus cisplatin; DP, docetaxel plus cisplatin; TC, paclitaxel plus carboplatin.

* p value with Mantel test compared to AP.